Evidence map›Paper›PMID 39330306›Full record

ReviewMarine drugs2024

Synthesis of Marine (−)-Pelorol and Future Perspectives.

Antonio Rosales Martínez, Ignacio Rodríguez-García

Abstract readReview
In one paragraph

Review in Marine drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Antonio Rosales MartínezDepartment of Chemical Engineering, Escuela Politécnica Superior, University of Sevilla, 41011 Sevilla, Spain.ORCID 0000-0003-0182-0548
Ignacio Rodríguez-GarcíaOrganic Chemistry, CeiA3, CIAIMBITAL, University of Almería, 04120 Almeria, Spain.ORCID 0000-0002-2985-8567

Funding

European Commission Horizon 2020-Research and Innovation Framework Program of the European Commission, project 101022507 LAURELINUniversidad Almería Fortalecimiento de Grupos 2023/88Universidad Sevilla Projects 2020/00001014 and 2021/00000422: Ayudas a Consolidación de Grupos de la Junta de Andalucía and Project Politec-Biomat: Red de Biomateriales en la Universidad de Sevilla
6 · The paper itself

Abstract

Meroterpenoid-type marine natural compounds have attracted an increasing amount of attention due to their peculiar chemical structures and their potential for the development of therapeutically important probes. Within this group of substances pelorol stands out; it is a natural compound isolated from marine organisms with a unique structure and an interesting biological profile. In this article, we summarize and highlight the most interesting aspects of the synthetic procedures towards this compound, which have two common key steps. The first is the coupling of a drimanyl derivative with a compound derived from an arene. The second is a Friedel-Crafts cyclization which forms the C ring of the natural product. Despite the synthetic advances achieved so far, we consider that a more efficient synthetic procedures could be carried out, since their synthetic routes are difficult to scale up due to numerous reaction steps and the limitations imposed by the use of some reagents. In this article, we present a new and versatile retrosynthetic analysis of (−)-pelorol and analogs, which is highly desirable for their easy preparation and subsequent broad study of their biological activities. This is a retrosynthetic route that could improve those reported in the literature in terms of cost-effectiveness.

Indexed as

Aquatic OrganismsBiological ProductsAnimalsCyclizationMolecular StructureSesquiterpenesTerpenesBiological ProductsSesquiterpenesTerpenesmarine natural productsmeroterpenoidspelorol

Identifiers

PMID39330306
PMCPMC11433074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.